[go: up one dir, main page]

SG11201707325RA - Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) - Google Patents

Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)

Info

Publication number
SG11201707325RA
SG11201707325RA SG11201707325RA SG11201707325RA SG11201707325RA SG 11201707325R A SG11201707325R A SG 11201707325RA SG 11201707325R A SG11201707325R A SG 11201707325RA SG 11201707325R A SG11201707325R A SG 11201707325RA SG 11201707325R A SG11201707325R A SG 11201707325RA
Authority
SG
Singapore
Prior art keywords
micrornas
mirnas
risk
detecting
determining
Prior art date
Application number
SG11201707325RA
Inventor
Heng-Phon Too
Lihan Zhou
Ruiyang Zou
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201707325RA publication Critical patent/SG11201707325RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Plant Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
SG11201707325RA 2015-03-09 2016-03-09 Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) SG11201707325RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201501781W 2015-03-09
PCT/SG2016/050113 WO2016144265A1 (en) 2015-03-09 2016-03-09 Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)

Publications (1)

Publication Number Publication Date
SG11201707325RA true SG11201707325RA (en) 2017-10-30

Family

ID=56880404

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707325RA SG11201707325RA (en) 2015-03-09 2016-03-09 Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
SG10201908277T SG10201908277TA (en) 2015-03-09 2016-03-09 Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201908277T SG10201908277TA (en) 2015-03-09 2016-03-09 Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)

Country Status (6)

Country Link
US (1) US12188092B2 (en)
EP (2) EP3916106A1 (en)
CN (3) CN116064801A (en)
ES (1) ES2882104T3 (en)
SG (2) SG11201707325RA (en)
WO (1) WO2016144265A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106729751B (en) * 2015-11-20 2020-03-06 中国医学科学院肿瘤医院 Use of a microRNA molecule for detection and treatment of breast cancer
WO2018056432A1 (en) * 2016-09-26 2018-03-29 東レ株式会社 Method for detecting hemolysis in blood sample and hemolysis detection chip
US11976330B2 (en) * 2017-04-06 2024-05-07 The University Of Vermont And State Agricultural College MiRNA signature expression in cancer
WO2019081610A1 (en) * 2017-10-24 2019-05-02 Universite Paris Descartes DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING ONE OR MORE miRNA AS A BIOMARKER
CN107815492A (en) * 2017-12-08 2018-03-20 武汉科技大学 A kind of detection method based on QPCR Diagnosis of Breast cancers
JP7298913B2 (en) * 2017-12-13 2023-06-27 国立大学法人広島大学 Methods to Aid in Breast Cancer Detection
GB201802404D0 (en) * 2018-02-14 2018-03-28 Univ Malta Methods
CN108531586B (en) * 2018-03-19 2022-03-29 朱伟 Circulating miRNA marker on X chromosome related to breast cancer auxiliary diagnosis and application thereof
CN109337978B (en) * 2018-07-03 2023-12-01 华中科技大学同济医学院附属同济医院 Application of miRNA in preparation of advanced serous epithelial ovarian cancer chemotherapy drug resistance evaluation kit
CN108950003B (en) * 2018-09-10 2022-02-11 山东大学齐鲁医院 A miRNA marker for diagnosing breast cancer and application of miRNA
CN109182524A (en) * 2018-09-29 2019-01-11 江苏医诺万细胞诊疗有限公司 MiRNA combination marker and its application of a kind of auxiliary diagnosis cervical carcinoma and its precancerous lesion
CN109609630B (en) * 2018-12-03 2023-01-13 哈尔滨医科大学 Molecular marker for early gastric cancer diagnosis and application thereof
CN109295233A (en) * 2018-12-10 2019-02-01 复旦大学附属中山医院 A kit for combined detection of miRNA in the diagnosis of colorectal cancer
CN109609633B (en) * 2018-12-24 2022-02-11 朱伟 Serum miRNA marker related to breast cancer auxiliary diagnosis and application thereof
CN109593851B (en) * 2018-12-24 2022-02-11 朱伟 Plasma miRNA marker related to breast cancer auxiliary diagnosis and application thereof
CN115537466A (en) * 2019-04-30 2022-12-30 觅瑞实验室私人有限公司 A miRNA marker combination and kit for detecting gastric cancer
EP3772543B1 (en) * 2019-08-09 2023-09-27 Albert-Ludwigs-Universität Freiburg Method for diagnosing breast cancer
CN112516155A (en) * 2019-09-18 2021-03-19 四川大学华西医院 Gene therapy preparation for three-negative breast cancer
CN110804659B (en) * 2019-10-23 2023-02-03 华南农业大学 Application of serum exosome ssc-miR-92b-3p as molecular marker for early pregnancy diagnosis of sows
CN110699444A (en) * 2019-11-05 2020-01-17 中国人民解放军63919部队 Serum/plasma miRNA marker related to ankylosing spondylitis and application thereof
CN110787181B (en) * 2019-12-10 2022-11-15 合肥市第二人民医院 Group of miRNA and application thereof in biological targeted therapy of breast cancer
CN112980947A (en) * 2019-12-12 2021-06-18 中国科学院大连化学物理研究所 Primer and kit for detecting circulating microRNA (microribonucleic acid) related to lung cancer diagnosis and treatment
CA3169677A1 (en) * 2020-02-27 2021-09-02 The Trustees Of The University Of Pennsylvania Methods of using a multi-analyte approach for diagnosis and staging a disease
CN111653315A (en) * 2020-05-29 2020-09-11 杭州广科安德生物科技有限公司 Method for constructing mathematical model for detecting breast cancer in vitro and application thereof
CN111518914B (en) * 2020-06-09 2021-12-24 上海圣梓茂生物科技有限公司 MiRNA marker combination, kit and method for detecting breast cancer
WO2022051141A1 (en) * 2020-09-03 2022-03-10 The Trustees Of Indiana University Methods for early detection of breast cancer
CN113151477B (en) * 2021-05-08 2022-04-15 武汉大学中南医院 miRNA marker for detecting intestinal cancer and application thereof
CN113215256A (en) * 2021-05-10 2021-08-06 深圳市展行生物有限公司 Method for evaluating breast cancer risk and miRNA combination used in same
CN118043484A (en) * 2021-08-02 2024-05-14 新加坡国立大学 Circulating microRNA panel and method for early detection of breast cancer
CN117844930B (en) * 2021-11-26 2024-07-02 馥鼎(上海)生物医药有限公司 Breast cancer diagnosis model and method for diagnosing or prognosis evaluating breast cancer
CN114141309A (en) * 2021-11-29 2022-03-04 湖州市中心医院 miRNAs that co-regulate ADRM1 and TP53 and their screening methods
US20250191759A1 (en) 2022-03-11 2025-06-12 Adriana DE SIERVI Breast Cancer Diagnostic and Treatment
WO2024089689A1 (en) * 2022-10-25 2024-05-02 Clonal Ltd Methods for detection of breast cancer
JP2024086170A (en) * 2022-12-16 2024-06-27 株式会社東芝 Analytical method, kit and detection device
KR102583229B1 (en) * 2023-03-15 2023-09-27 재단법인 전남바이오산업진흥원 Composition for preventing or treating cerebral infarction
IT202300013221A1 (en) * 2023-06-27 2024-12-27 Fondazione I R C C S St Neurologico Carlo Besta MicroRNAs as Diagnostic Biomarkers and Therapeutic Agents for Small Fiber Neuropathy
WO2025014839A1 (en) * 2023-07-07 2025-01-16 Exai Bio Inc. Systems and methods for detection of non-coding rnas
DE102023134350A1 (en) * 2023-12-07 2025-06-12 Rheinisch-Westfälische Technische Hochschule Aachen, Körperschaft des öffentlichen Rechts miRNA marker profiles of breast cancer subtypes from urine samples
CN119193819B (en) * 2024-11-28 2025-05-13 苏州麦锐克生物科技有限公司 Multiple miRNA markers and kit for Alzheimer disease diagnosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183393B1 (en) * 2007-09-06 2014-06-11 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
AU2010265889A1 (en) * 2009-06-25 2012-01-19 Yale University Single nucleotide polymorphisms in BRCA1 and cancer risk
CN101988061A (en) * 2009-07-30 2011-03-23 江苏命码生物科技有限公司 Breast cancer detecting marker as well as detecting method, kit and biological chip thereof
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
US20130065778A1 (en) 2010-01-26 2013-03-14 Yale University MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy
CN101921760B (en) * 2010-09-08 2012-02-01 南京医科大学 A serum/plasma miRNA marker associated with breast cancer and its application
AU2012324531B2 (en) * 2011-10-19 2018-03-22 Council Of Scientific And Industrial Research (C.S.I.R.) Biomarkers useful for detection of types, grades and stages of human breast cancer
NO3051026T3 (en) * 2011-10-21 2018-07-28
WO2013190091A1 (en) * 2012-06-21 2013-12-27 Ruprecht-Karls-Universität Heidelberg CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
WO2014129975A1 (en) 2013-02-20 2014-08-28 Singapore Health Services Pte Ltd Identification of circulating microrna signatures for breast cancer detection
EP2961386B1 (en) 2013-02-28 2019-07-10 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014193309A1 (en) * 2013-05-30 2014-12-04 Agency For Science, Technology And Research Method For Determining Cancer Prognosis

Also Published As

Publication number Publication date
EP3268494B1 (en) 2021-04-21
ES2882104T3 (en) 2021-12-01
CN116064801A (en) 2023-05-05
HK1249555A1 (en) 2018-11-02
SG10201908277TA (en) 2019-10-30
CN116064800A (en) 2023-05-05
US20180230544A1 (en) 2018-08-16
EP3268494A4 (en) 2018-11-07
EP3268494A1 (en) 2018-01-17
CN107429295B (en) 2022-09-30
EP3916106A1 (en) 2021-12-01
CN107429295A (en) 2017-12-01
WO2016144265A1 (en) 2016-09-15
US12188092B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
SG11201707325RA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
ZA202007633B (en) Modified guide rnas
IL255125A0 (en) Evaluation of cas9 molecule/guide rna molecule complexs
SG10202011339RA (en) Microrna biomarker for the diagnosis of gastric cancer
GB201511152D0 (en) Method of diagnosing bladder cancer
ZA201701753B (en) Biomarkers for assessing breast cancer
SG10202102509TA (en) Micrornas as biomarkers for endometriosis
IL251376A0 (en) Methods for assessing risk of developing breast cancer
TWD174576S (en) Portion of an analyte meter
AU364937S (en) Breastshield-connector for breast pump
SG11201706544SA (en) Breast shield
IL250110A0 (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
ZA201803445B (en) Apparatus for determining the weight of an object
EP3298145A4 (en) Method of diagnosis of breast cancer
EP3122905A4 (en) Circulating micrornas as biomarkers for endometriosis
PL3189336T3 (en) Method for determining risk of pre-eclampsia
ZA201707313B (en) Specific detection of clusterin isoforms
EP3361237A4 (en) TOMOGRAPHY METHOD
GB201406822D0 (en) Method of designing guide vane formations
GB201512602D0 (en) Method of modelling biomarkers
ZA201804318B (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
EP3360959A4 (en) METHOD OF DETERMINING TUMORS
GB201802885D0 (en) Method of neutron tomography
EP3338095A4 (en) METHOD OF DETECTING CANCER
GB201617722D0 (en) Method for determining prognosis of cancer